TORL BioTherapeutics Raises $158M in Funding for Cancer Treatment Development

TORL BioTherapeutics' Series B-2 Funding

Key Highlights:

• Series B-2 Funding: Raised $158 million in Series B-2 funding, bringing the total amount to $350 million.
• Investors: Deep Track Capital led the round, with participation from RA Capital Management, Perceptive Advisors, and Avidity Partners, as well as existing investors such as Goldman Sachs Alternatives, UC Investments, Bristol Myers Squibb, and more.
• Development Plans: Funds will be used to continue the clinical development of TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500 for the treatment of various tumors and cancers.

TORL BioTherapeutics' Target Market

• Target Market: Patients challenged with a variety of human malignancies, including CLDN 6+ tumors, CLDN 18.2+ solid tumors, CDH17+ colorectal cancer, and DLK1 positive solid tumors.
• Biopharmaceutical Companies: Potential partners for collaboration in the development and commercialization of new antibodies and drug conjugates.
• Research Institutions: Collaborations with research institutions for further research and development of biologics-based drugs.

What TORL BioTherapeutics Needs to Buy

• Clinical Research and Development Services: Collaborations with clinical research organizations for conducting clinical trials and advancing drug development.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers for the production and distribution of antibodies and drug conjugates.
• Regulatory and Compliance Expertise: Engaging with regulatory consultants and experts to navigate the complex regulatory landscape in the biopharmaceutical industry.